Sign in
CompletedPhase 2

Cannabidiol and Prolonged Exposure

Key facts

Who runs it
VA Office of Research and Development
Where
San Diego, United StatesSee the site
Trial code
Status
Completed
Phase
Phase 2
People taking part
144 people enrolled
Started
1 Oct 2019
Ended
30 Sept 2025
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Prolonged Exposure
  • Cannabidiol
  • placebo
Record updated
17 November 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 16 criteriaShow less

Who can take part

  • Over the age of 18 at the time of screening
  • Judged by the study physician to be in generally good health
  • Meet clinical criteria for Posttraumatic Stress Disorder (PTSD) on the Clinician-Administered PTSD Scale for DSM-5 (CAPS-5)
  • Negative urine pregnancy test

Who cannot take part

  • Patient is currently prescribed medications with possible CBD-drug interactions
  • Positive drug screen for THC, barbiturates, amphetamines (if not prescribed), benzodiazepines, and/or opiates
  • History of significant allergic condition, significant drug-related hypersensitivity, or allergic reaction to cannabinoids
  • Current or past DSM-5 diagnosis of dissociative identity disorder, eating disorder with active purging, personality disorders, primary psychotic disorder, or bipolar affective disorder type 1
  • History of actual suicide attempt in the last 5 years
  • History of treatment for, or evidence of, moderate to severe alcohol or drug abuse within the past year or regular alcohol consumption exceeding recommended limits
  • Lifetime history of Cannabis Use Disorder
  • Used cannabis, synthetic cannabinoid, cannabinoid analogue, or any CBD or THC-containing product within 30 days of eligibility screening
  • Patient has had a change in psychopharmacotherapy regimen in the last 4 weeks, or has any plans to change regimen over the course of the study
  • Patient is engaged in trauma-related psychotherapy for PTSD
  • Unmanaged obstructive sleep apnea
  • Pregnant or breastfeeding

Where in United States

  • VA San Diego Healthcare System, San Diego, CASan Diego, United States

About the trial

What the trial wants to find out

The trial will include a randomized control trial to evaluate the efficacy of using Cannabidiol (CBD), a non-intoxicating cannabinoid, as an adjunctive to Prolonged Exposure therapy (PE). The trial will compare PE + CBD to PE + placebo in a sample of 136 military Veterans with PTSD at the VA San Diego Medical Center. The study represents the logical and innovative next step for augmenting existing treatments and developing novel pharmacotherapy for PTSD. Findings from the proposed RCT will inform clinical practice and policy by investigating whether administration of CBD in the context of PE therapy will improve treatment outcomes for military Veterans with PTSD.

The 2 groups in the trial

  • Prolonged Exposure + CannabidiolTreatment being tested

    Psychotherapy plus active medication

    Treatment: Prolonged Exposure and Cannabidiol

  • Prolonged Exposure + PlaceboExisting treatment, for comparison

    Psychotherapy plus placebo medication

    Treatment: Prolonged Exposure and placebo

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Cannabidiol as an Adjunctive to Prolonged Exposure for the Treatment of PTSD
Record updated
17 November 2026